Liver kinase B1 (LKB1) has been shown to be involved in many cancers. However, the underlying mechanism remains unclear. This study aimed to reveal the mechanism through which LKB1 performs its role in lung cancer. LKB1 shRNA and overexpression plasmid were employed to investigate the role of LKB1 in lung cancer in vitro and in vivo. The involvement of Shh signaling pathway was assessed by western blot. Silencing LKB1 promoted migration, invasion and angiogenesis of lung cancer cells, while overexpression of LKB1 led to the opposite. Further study showed that Shh signaling pathway is suppressed by LKB1. Cyclopamine, a Shh signaling pathway inhibitor, reduced the effects of LKB1 silencing, indicating that LKB1 inhibits migration, invasion and angiogenesis through suppressing the Shh signaling pathway. In vivo study also showed that Shh signaling pathway is involved in the modulation of LKB1 in metastasis and angiogenesis of lung cancer. Our study demonstrates that LKB1 inhibits metastasis and angiogenesis of lung cancer through suppressing the Shh signaling pathway.